ANL News

The third quarter wrapped up with four IPOs and eight pipeline additions. Oncology biotech Adlai Nortye (ANL) raised $58 million at an $849 million market cap. The company originally planned to raise $72 million in August but never priced; it removed and then set new terms earlier this month. Operating through subsidiaries in the US and China, Adlai...read more

Adlai Nortye, a Phase 3 biotech developing immunotherapies for various cancers, raised $58 million by offering 2.5 million ADSs at $23, as expected. A potential investor had indicated on $50 million worth of ADSs in the offering (87% of the deal), and the company had planned to raise an additional $40 million in a concurrent private placement to Nippon Kayaku. Operating through...read more

Adlai Nortye, a Phase 3 biotech developing immunotherapies for various cancers, announced terms for its IPO on Wednesday. The Cayman Islands-based company plans to raise $58 million by offering 2.5 million ADSs at $23. A potential investor intends to purchase $50 million worth of ADSs in the offering (87% of the deal), and the company plans to raise an additional $40 million in a...read more

Adlai Nortye, a Phase 3 biotech developing immunotherapies for various cancers, submitted a blank filing on Tuesday, after setting terms last month to raise $72 million by offering 3 million ADSs at a price range of $22 to $26. In its latest filing, the company also removed CITIC CLSA as an underwriter, leaving Cantor Fitzgerald as sole bookrunner, and disclosed financials for...read more